XML 44 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Revenues:        
Revenue under collaborative research and development arrangements $ 1,114,952 $ 8,388,760 $ 5,658,460 $ 8,417,330
Revenue under collaborative research and development arrangements with affiliated entity 112,500 106,250 366,964 318,750
Grants and miscellaneous revenue 612,901 991,835 1,974,234 2,991,600
Total revenues 1,840,353 9,486,845 7,999,658 11,727,680
Operating expenses:        
Research and development 7,017,805 5,438,405 24,850,566 14,964,599
General and administrative 3,153,714 3,282,796 11,633,259 9,303,535
Gain on sale of assets 0 0 0 (1,000,000)
Total operating expenses 10,171,519 8,721,201 36,483,825 23,268,134
Income (Loss) from operations (8,331,166) 765,644 (28,484,167) (11,540,454)
Other income (expense):        
Interest and other income, net 97,174 46,787 218,249 123,638
Change in fair value of common stock warrants (113,980) (34,952,210) 204,484 (39,579,704)
Gain (Loss) on investment in affiliated entity 1,168,911 3,248,926 (666,212) 380,791
Net loss (7,179,061) (30,890,853) (28,727,646) (50,615,729)
Net loss attributable to non-controlling interest 1,486 13,443 17,337 41,611
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (7,177,575) $ (30,877,410) $ (28,710,309) $ (50,574,118)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders:        
Basic (in USD per share) $ (0.12) $ (0.64) $ (0.49) $ (1.15)
Diluted (in USD per share) $ (0.12) $ (0.64) $ (0.52) $ (1.15)
Weighted average number of common shares outstanding used in per share calculations:        
Basic (in shares) 60,392,911 47,989,039 58,625,740 44,045,769
Diluted (in shares) 60,602,831 47,989,039 58,936,414 44,045,769